title: [Conservative approach in children with central line infection].
abstract: In 1994-1995, central venous lines were placed in 47 children. All except 1 were of the Broviac type, with subcutaneous tunneling via the internal or external jugular vein. Ages were between 7 days and 16 years. Indications for central venous cannulation were chemotherapy (35 cases), TPN (5), prolonged parenteral antibiotics (4), and repeated blood transfusions (3). The catheter was the source of infection in 13 children (28%), 11 of whom were immunocompromised. The commonly identified bacteria were Staphylococcus aureus (4 cases), Pseudomonas aeruginosa (4), coagulase-negative Staphylococcus (2), and various gram-negative rods (3). All cases were treated with antibiotics through the catheter. The most commonly used were oxacillin (4), ceftazidime (4), and amikacin (4). In 10, treatment succeeded without having to remove the line. In 2 others, tunnel infection developed and the catheter had to be removed. 1 child forcefully removed his catheter before treatment could be started. There were no further complications in the group treated conservatively, except for a case of superior vena cava thrombosis in a girl with recurrent infection of the tunnel. In 7 out of 13 treatment was continued and completed at home. This saved 65 days of hospitalization out of 210. We conclude that the conservative approach to treatment is feasible in most cases of infection when the source is the central venous catheter itself. However, when the tunnel is infected, conservative treatment may be ineffective. Treatment can be carried out in the home, with economy in cost and in use of hospital beds, and is preferred by patients and their parents.
authors.affiliation: Dept. of Pediatric Surgery, and Hematology, Bnei-Zion Medical Center, Technion, Haifa.
authors.forename: Z
authors.initials: Z
authors.lastname: Steiner
authors.forename: Y
authors.initials: Y
authors.lastname: Kandelis
authors.forename: G
authors.initials: G
authors.lastname: Mogilner
authors.forename: D
authors.initials: D
authors.lastname: Atias
authors.forename: I
authors.initials: I
authors.lastname: Srugo
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology*; D001803:Blood Transfusion; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010289:Parenteral Nutrition, Total
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents